FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1285-1287 March 31, 2005 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Controversy over recent revelations concerning the adverse cardiovascular effects of selective cyclooxygenase-2 (COX-2) inhibitors has generally been framed as a story of regulatory failure, in which the Food and Drug Administration (FDA) has failed in its mission to protect the public from unsafe products. But this simplistic understanding of the mission of the FDA seems to make failure all but inevitable, if the reliable observation of the risks and benefits of a drug requires rigorous long-term studies. Perhaps in an earlier era the goal of drug regulation was simply to protect the public from poisons.¹ Today, drug regulation guides the . . . [Full Text of this Article]

Source Information

Ms. Eisenberg is a professor of law at the University of Michigan Law School, Ann Arbor.

This article has been cited by other articles:

• Aberegg, S. K., Arkes, H., Terry, P. B. (2006). Failure to Adopt Beneficial Therapies Caused by Bias in Medical Evidence Evaluation.. Med Decis Making 26: 575-582 [Abstract]  
• Olson, D. M. (2005). The Promise of Prostaglandins: Have They Fulfilled Their Potential as Therapeutic Targets for the Delay of Preterm Birth?. Reproductive Sciences 12: 466-478 [Abstract]